Search Results - "Piciocchi A, A"

Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study by Voso, M.T., Leone, G., Piciocchi, A., Fianchi, L., Santarone, S., Candoni, A., Criscuolo, M., Masciulli, A., Cerqui, E., Molteni, A., Finelli, C., Parma, M., Poloni, A., Carella, A.M., Spina, F., Cortelezzi, A., Salvi, F., Alessandrino, E.P., Rambaldi, A., Sica, S.

“…Allogeneic stem-cell transplantation (HSCT) is the only curative treatment in myelodysplastic syndromes (MDS). Azacitidine (AZA) is increasingly used prior to…”
Get full text

Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy by Girmenia, C, Rossolini, G M, Piciocchi, A, Bertaina, A, Pisapia, G, Pastore, D, Sica, S, Severino, A, Cudillo, L, Ciceri, F, Scimè, R, Lombardini, L, Viscoli, C, Rambaldi, A

“…Infections by carbapenem-resistant Klebsiella pneumoniae (CRKp) represent a challenging problem after SCT. A retrospective survey (January 2010 to July 2013)…”
Get full text

Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine by Breccia, M., Piciocchi, A., Messina, M., Soddu, S., De Stefano, V., Bellini, M., Iurlo, A., Martino, B., Siragusa, S., Albano, F., Mora, B., Fazi, P., Vignetti, M., Guglielmelli, P., Palandri, F.

Get full text

PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy by Cicconi, L, Divona, M, Ciardi, C, Ottone, T, Ferrantini, A, Lavorgna, S, Alfonso, V, Paoloni, F, Piciocchi, A, Avvisati, G, Ferrara, F, Di Bona, E, Albano, F, Breccia, M, Cerqui, E, Sborgia, M, Kropp, M G, Santoro, A, Levis, A, Sica, S, Amadori, S, Voso, M T, Mandelli, F, Lo-Coco, F

“…The APL0406 study showed that arsenic trioxide (ATO) and all -trans retinoic acid (ATRA) are not inferior to standard ATRA and chemotherapy (CHT) in newly…”
Get full text

Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group by Fazio, F., Passucci, M., Micozzi, J., Di Landro, F., Fianchi, L., Za, T., Manieri, V. M., Annibali, O., Cupelli, L., Bongarzoni, V., Gentili, S., De Padua, L., Crisanti, E., Garzia, M. G., Rago, A., Piciocchi, A., Mengarelli, A., Morè, S., De Stefano, V., Bafti, M. S., Martelli, M., Petrucci, M. T.

Get full text

Long term mortality and morbidity of Italian soldiers after deployment in Iraq as related to biomarkers assessment: Results of the SIGNUM study by De Angelis, R., Piciocchi, A., Bugani, M., Rossi, S., Lastilla, M., Vento, R., Autore, A., Sebastiani, N., Palomba, S., Manno, V., Battilomo, S., Belmonte, S., Pulliero, A., Izzotti, A.

“…The health profile of military veterans deployed in foreign operative theatres was assessed by several international studies because of potential exposure to…”
Get full text

Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group by Vozella, Federico, Siniscalchi, A., Rizzo, M., Za, T., Antolino, G., Coppetelli, U., Piciocchi, A., Andriani, A., Annibali, O., De Rosa, L., Cimino, G., La Verde, G., De Stefano, V., Cantonetti, M., di Toritto, T. Caravita, Petrucci, M. T.

“…Daratumumab (DARA) is a human IgG-K monoclonal antibody (MoAb) targeting CD38 that is approved alone or in combination with bortezomib and dexamethasone or…”
Get full text

Genetic landscape of ultra-stable chronic lymphocytic leukemia patients by Raponi, S., Del Giudice, I., Marinelli, M., Wang, J., Cafforio, L., Ilari, C., Piciocchi, A., Messina, M., Bonina, S., Tavolaro, S., Bordyuh, M., Mariglia, P., Peragine, N., Mauro, F.R., Chiaretti, S., Molica, S., Gentile, M., Visentin, A., Trentin, L., Rigolin, G.M., Cuneo, A., Diop, F., Rossi, D., Gaidano, G., Guarini, A., Rabadan, R., Foà, R.

“…Chronic lymphocytic leukemia (CLL) has a heterogeneous clinical course. Beside patients requiring immediate treatment, others show an initial indolent phase…”
Get full text

Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial by Cortelezzi, A, Sciumè, M, Liberati, A M, Vincenti, D, Cuneo, A, Reda, G, Laurenti, L, Zaja, F, Marasca, R, Chiarenza, A, Gritti, G, Orsucci, L, Storti, S, Angelucci, E, Cascavilla, N, Gobbi, M, Mauro, F R, Morabito, F, Fabris, S, Piciocchi, A, Vignetti, M, Neri, A, Rossi, D, Giannarelli, D, Guarini, A, Foà, R

“…We conducted a phase II, noncomparative, open-label, multicenter GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) study (CLL0809) to assess the…”
Get full text

Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients by Buccisano, F., Maurillo, L., Piciocchi, A., Del Principe, M. I., Sarlo, C., Cefalo, M., Ditto, C., Di Veroli, A., De Santis, G., Irno Consalvo, M., Fraboni, D., Panetta, P., Palomba, P., Attrotto, C., Del Poeta, G., Sconocchia, G., Lo-Coco, F., Amadori, S., Venditti, A.

“…In the present analysis, we evaluated whether in elderly acute myeloid leukemia (AML) patients (>60 years), minimal residual disease (MRD) assessed by flow…”
Get full text

Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia by Buccisano, F, Maurillo, L, Piciocchi, A, Del Principe, M I, Picardi, A, Cerretti, R, Cudillo, L, De Angelis, G, Sarlo, C, Cefalo, M, Ditto, C, Di Veroli, A, Mariotti, B, Nasso, D, De Bellis, E, Del Poeta, G, Voso, M T, Sconocchia, G, Lo Coco, F, Arcese, W, Amadori, S, Venditti, A

Get full text

Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile by Giudice, I Del, Rigolin, G M, Raponi, S, Cafforio, L, Ilari, C, Wang, J, Bordyuh, M, Piciocchi, A, Marinelli, M, Nanni, M, Tavolaro, S, Filetti, M, Bardi, A, Tammiso, E, Volta, E, Negrini, M, Saccenti, E, Mauro, F R, Rossi, D, Gaidano, G, Guarini, A, Rabadan, R, Cuneo, A, Foà, R

Get full text

P04 MULTIPARAMETRIC FLOW CYTOMETRY REFINES RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS by Fazio, F., Lapietra, G., Limongi, M. Z., Intoppa, S., Milani, M. L., Piciocchi, A., Martelli, M., Guarini, A., Foà, R., De Propris, M. S., Petrucci, M. T.

Get full text

Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine by Voso, M T, Fabiani, E, Piciocchi, A, Matteucci, C, Brandimarte, L, Finelli, C, Pogliani, E, Angelucci, E, Fioritoni, G, Musto, P, Greco, M, Criscuolo, M, Fianchi, L, Vignetti, M, Santini, V, Hohaus, S, Mecucci, C, Leone, G

Get full text

S244: EFFECT OF ANTI‐SPIKE NEUTRALIZING MONOCLONAL ANTIBODIES ON COVID‐19 PROGRESSION AND TIME TO VIRAL CLEARANCE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND SARS‐COV‐2 INFECTION: THE GIMEMA EXPERIENCE by Marasco, V., Guidetti, A., Piciocchi, A., Candoni, A., Bocchia, M., Bruna, R., Musto, P., Visentin, A., Turrini, M., Tucci, A., Selleri, C., Crea, E., Fazi, P., Passamonti, F., Corradini, P.

Get full text

P23: RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS. A MULTICENTER RETROSPECTIVE ANALYSIS OF ELIGIBILITY CRITERIA FOR CAR‐T CELL THERAPY by Fazio, F, Di Rocco, A, Za, T, Tomarchio, V, Rago, A, Piciocchi, A, Caravita di Toritto, T, Annibali, O, De Stefano, V, Foà, R, Martelli, M, Petrucci, MT

Get full text

P25 EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP by Fazio, F., Passucci, M., Lisi, C., Micozzi, J., Fianchi, L., Di Landro, F., Za, T., Gumenyuk, S., Ferraro, S., Anaclerico, B., De Padua, L., Annibali, O., Rago, A., Piciocchi, A., Bongarzoni, V., Cupelli, L., Mengarelli, A., De Stefano, V., Martelli, M., Petrucci, M.T.

Get full text

P353: FORTY MONTHS UPDATE OF THE GIMEMA LAL2116 (D‐ALBA) PROTOCOL AND ANCILLARY LAL2217 STUDY FOR NEWLY DIAGNOSED ADULT PH+ ALL by Chiaretti, S., Bassan, R., Vitale, A., Elia, L., Piciocchi, A., Viero, P., Ferrara, F., Lunghi, M., Fabbiano, F., Bonifacio, M., Fracchiolla, N., Di Bartolomeo, P., Fazi, P., De Propris, M. S., Vignetti, M., Guarini, A., Rambaldi, A., Foà, R.

Get full text

Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes by Gurnari, C., Latagliata, R., Buccisano, F., Piciocchi, A., Fenu, S., Mancini, S., Fianchi, L., Criscuolo, M., Sarlo, C., Romano, A., Falconi, G., Niscola, P., Di Veroli, A., Breccia, M., Piccioni, A., Aloe-Spiriti, M.A., Lo-Coco, F., Voso, M.T.

Get full text

MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine by Visani, G, Loscocco, F, Ruzzo, A, Galimberti, S, Graziano, F, Voso, M T, Giacomini, E, Finelli, C, Ciabatti, E, Fabiani, E, Barulli, S, Volpe, A, Magro, D, Piccaluga, P, Fuligni, F, Vignetti, M, Fazi, P, Piciocchi, A, Gabucci, E, Rocchi, M, Magnani, M, Isidori, A

“…We evaluated the impact of genomic polymorphisms in folate-metabolizing, DNA synthesis and DNA repair enzymes on the clinical outcome of 108 patients with…”
Get full text